Antiretroviral Therapy Perspective

 
 
  • Drugs to Avoid in Patients on DOACs DOACs overall have substantially fewer drug-drug interactions than warfarin, but there are still a few to watch out for.
  • AIDS 2020 Read clinically focused news coverage of key developments from IAS 2020
  • Long-acting Injectable Cabotegravir for PrEP Is Promising   Dr Paul Sax discusses the interim results from a study on the use of the long-acting injectable cabotegravir for pre-exposure prophylaxis in cisgender men and transgender women who have sex with men.
  • The Promise of Remdesivir for COVID-19 Treatment   WebMD Chief Medical Officer John Whyte talks with Dr Stuart Cohen about remdesivir for the possible treatment of COVID-19 infection, and when we might expect to see the development of a vaccine.
  • Confronting the HIV Epidemic   Infectious disease experts from UNC Chapel Hill have developed innovative methods to engage young minority men, the fastest-growing HIV-positive population, in the prevention and treatment of HIV.
  • COVID-19 in People With HIV: Commonly Asked Questions   Dr Paul Sax gives answers to some of the most commonly asked questions he has received from patients with HIV.
  • Low-Level Viremia in HIV: When Should We Worry?   Is all low-level viremia in HIV the same, and does it lead to virologic failure? Dr Sax comments on a new study.
  • CROI 2020 Read clinically focused news coverage of key developments from CROI 2020
  • Infectious Diseases in 2020: 5 Areas of Concern   Dr Paul Auwaerter discusses advances made in infectious diseases in 2019 and looks ahead at concerns for the new year.
  • Time to Rethink Renal Dosing of Lamivudine?   Dose reductions of lamivudine may not be necessary for all patients with mild to moderate renal impairment, says Dr Paul Sax.
  • ANAC 2019 Read clinically focused news coverage of key developments from ANAC 2019
  • USCA 2019 Read clinically focused news coverage of key developments from UCSA 2019
  • Exploiting the CCR5 Receptor: Potential Avenue for HIV Cure?   CCR5- delta 32 mutation homozygosity is associated with increased mortality but may lead to a potential cure for HIV. Is it worth the risk?
  • IAS 2019 Read clinically focused news coverage of key developments from IAS 2019
  • PrEP and Risk for Sexually Transmitted Infections   Dr Paul Sax shares what he thinks is most interesting and useful about the findings that STI risk is elevated in PrEP users.
  • CROI 2019 Read clinically focused news coverage of key developments from CROI 2019
  • Two- vs Three-Drug Initial Therapy for HIV   Dr Paul Sax describes the potential clinical implications of the GEMINI studies.
  • A Precaution About PrEP in HIV Prevention   PrEP can reduce new HIV infections if taken as directed. So why do PrEP failures occur?
  • Preventing HPV in Patients With HIV: New Guidelines A degree of synergism may exist between these two viruses, so prevention of HPV in patients with HIV is critical.
  • HIV 2018 Read clinically focused news coverage of key developments from HIV Glasgow 2018.